Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Short term Debt (2020 - 2025)

Insight Molecular Diagnostics' Short term Debt history spans 6 years, with the latest figure at $1.1 million for Q3 2025.

  • For Q3 2025, Short term Debt rose 71.99% year-over-year to $1.1 million; the TTM value through Sep 2025 reached $1.1 million, up 71.99%, while the annual FY2024 figure was $228000.0, 90.15% down from the prior year.
  • Short term Debt for Q3 2025 was $1.1 million at Insight Molecular Diagnostics, up from $689000.0 in the prior quarter.
  • Across five years, Short term Debt topped out at $2.6 million in Q1 2021 and bottomed at $109000.0 in Q3 2022.
  • The 5-year median for Short term Debt is $614000.0 (2024), against an average of $841235.3.
  • The largest annual shift saw Short term Debt plummeted 92.73% in 2022 before it soared 2022.94% in 2023.
  • A 5-year view of Short term Debt shows it stood at $1.3 million in 2021, then plummeted by 91.7% to $109000.0 in 2022, then skyrocketed by 2022.94% to $2.3 million in 2023, then plummeted by 90.15% to $228000.0 in 2024, then soared by 363.16% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Short term Debt are $1.1 million (Q3 2025), $689000.0 (Q2 2025), and $433000.0 (Q1 2025).